Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Main Inclusion Criteria:

• The patient has schizophrenia, diagnosed according to DSM-IV-TR®.

• The patient has a CGI-S score from mildly ill to markedly ill at the Screening andBaseline Visit(s).

• The patient is in need of a change in the current antipsychotic treatment and in thejudgement of the investigator the patient would benefit from an extended treatmentwith a once-monthly formulation.

• The patient agrees to protocol-defined use of effective contraception.

Main Exclusion Criteria:

• The patient has any current psychiatric disorder or Axis I disorder (DSM-IV® criteria)other than schizophrenia established as the primary diagnosis.

• The patient is experiencing acute exacerbation of psychotic symptoms at the ScreeningVisit or between the Screening and Baseline Visits.

• The patient in the investigator's judgment has shown significant intolerance and/orlack of efficacy to oral aripiprazole, paliperidone or risperidone.

• The patient is at significant risk of harming himself/herself or others according tothe investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).

• The patient has a history of neuroleptic malignant syndrome.

• The patient has or has had significant medical condition that would expose him or herto an undue risk of a significant adverse event or interfere with assessments ofsafety or efficacy during the course of the study including, but not limited toneurological, hepatic, renal, metabolic, haematological, immunological,gastrointestinal, pulmonary, or cardiovascular disorders.

• The patient has a disease or takes medication that could, in the investigator'sopinion, interfere with the assessments of safety, tolerability, or efficacy, orinterfere with the conduct or interpretation of the study.

• The patient is, in the investigator's opinion, unlikely to comply with the protocol oris unsuitable for any reason.